124 related articles for article (PubMed ID: 32639043)
1. Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Doucette K; Lai C; Pohlmann PR
Breast J; 2020 Oct; 26(10):2031-2033. PubMed ID: 32639043
[TBL] [Abstract][Full Text] [Related]
2. Development of Monoclonal B-cell Lymphocytosis Shortly After Treatment with Nivolumab and Subsequent Progression to Chronic Lymphocytic Leukemia.
Jamali A; Nemovi K; Kaur J; Dasanu CA
J Oncol Pharm Pract; 2022 Jul; 28(5):1218-1221. PubMed ID: 35060786
[TBL] [Abstract][Full Text] [Related]
3. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
5. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.
Strati P; Nasr SH; Leung N; Hanson CA; Chaffee KG; Schwager SM; Achenbach SJ; Call TG; Parikh SA; Ding W; Kay NE; Shanafelt TD
Haematologica; 2015 Sep; 100(9):1180-8. PubMed ID: 26088927
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
7. An oral drug for chronic lymphocytic leukemia.
Koehler A
JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940
[TBL] [Abstract][Full Text] [Related]
9. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
11. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
12. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib-Induced Lymphocytosis: Cytological Features.
Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
[No Abstract] [Full Text] [Related]
14. Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Xu W; Yang S; Zhou K; Pan L; Li Z; Gao S; Zhou D; Hu J; Feng R; Huang H; Wang T; Li D; Ji M; Guo H; Zhao X; Wu B; Yu Y; Wang Y; Huang J; Novotny W; Li J
Leuk Lymphoma; 2023 Mar; 64(3):712-716. PubMed ID: 36799536
[No Abstract] [Full Text] [Related]
15. Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.
Agathangelidis A; Ljungström V; Scarfò L; Fazi C; Gounari M; Pandzic T; Sutton LA; Stamatopoulos K; Tonon G; Rosenquist R; Ghia P
Haematologica; 2018 May; 103(5):865-873. PubMed ID: 29449433
[TBL] [Abstract][Full Text] [Related]
16. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A
Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
Popp HD; Flach J; Brendel S; Ruppenthal S; Kleiner H; Seifarth W; Schneider S; Schulze TJ; Weiss C; Wenz F; Hofmann WK; Fabarius A
Leuk Lymphoma; 2019 Mar; 60(3):795-804. PubMed ID: 30376743
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study.
Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Osterborg A
Br J Haematol; 2001 Jan; 112(1):155-60. PubMed ID: 11167796
[TBL] [Abstract][Full Text] [Related]
20. Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib.
Tang J; Zhong J; Yang Z; Su Q; Mo W
Biochem Biophys Res Commun; 2023 Apr; 650():96-102. PubMed ID: 36774689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
